BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 12019088)

  • 1. Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293.
    Betz UA; Fischer R; Kleymann G; Hendrix M; Rübsamen-Waigmann H
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1766-72. PubMed ID: 12019088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Helicase primase: targeting the Achilles heel of herpes simplex viruses.
    Kleymann G
    Antivir Chem Chemother; 2004 May; 15(3):135-40. PubMed ID: 15266895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics-pharmacodynamics of the helicase-primase inhibitor pritelivir following treatment of wild-type or pritelivir-resistant virus infection in a murine herpes simplex virus 1 infection model.
    Biswas S; Sukla S; Goldner T; Field HJ; Kropeit D; Paulsen D; Welbers A; Ruebsamen-Schaeff H; Zimmermann H; Birkmann A
    Antimicrob Agents Chemother; 2014 Jul; 58(7):3843-52. PubMed ID: 24752278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The helicase primase inhibitor, BAY 57-1293 shows potent therapeutic antiviral activity superior to famciclovir in BALB/c mice infected with herpes simplex virus type 1.
    Biswas S; Jennens L; Field HJ
    Antiviral Res; 2007 Jul; 75(1):30-5. PubMed ID: 17175035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease.
    Crute JJ; Grygon CA; Hargrave KD; Simoneau B; Faucher AM; Bolger G; Kibler P; Liuzzi M; Cordingley MG
    Nat Med; 2002 Apr; 8(4):386-91. PubMed ID: 11927945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Superior efficacy of helicase-primase inhibitor BAY 57-1293 for herpes infection and latency in the guinea pig model of human genital herpes disease.
    Baumeister J; Fischer R; Eckenberg P; Henninger K; Ruebsamen-Waigmann H; Kleymann G
    Antivir Chem Chemother; 2007; 18(1):35-48. PubMed ID: 17354650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Helicase-primase inhibitors for herpes simplex virus: looking to the future of non-nucleoside inhibitors for treating herpes virus infections.
    Biswas S; Sukla S; Field HJ
    Future Med Chem; 2014 Jan; 6(1):45-55. PubMed ID: 24358947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Helicase primase inhibitors (HPIs) are efficacious for therapy of human herpes simplex virus (HSV) disease in an infection mouse model.
    Uhlig N; Donner AK; Gege C; Lange F; Kleymann G; Grunwald T
    Antiviral Res; 2021 Nov; 195():105190. PubMed ID: 34666109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The helicase-primase inhibitor BAY 57-1293 reduces the Alzheimer's disease-related molecules induced by herpes simplex virus type 1.
    Wozniak MA; Frost AL; Itzhaki RF
    Antiviral Res; 2013 Sep; 99(3):401-4. PubMed ID: 23867133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of a helicase-primase inhibitor in animal models of ocular herpes simplex virus type 1 infection.
    Kaufman HE; Varnell ED; Gebhardt BM; Thompson HW; Atwal E; Rübsamen-Waigmann H; Kleymann G
    J Ocul Pharmacol Ther; 2008 Feb; 24(1):34-42. PubMed ID: 18201137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations close to functional motif IV in HSV-1 UL5 helicase that confer resistance to HSV helicase-primase inhibitors, variously affect virus growth rate and pathogenicity.
    Biswas S; Tiley LS; Zimmermann H; Birkmann A; Field HJ
    Antiviral Res; 2008 Oct; 80(1):81-5. PubMed ID: 18539344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease.
    Kleymann G; Fischer R; Betz UA; Hendrix M; Bender W; Schneider U; Handke G; Eckenberg P; Hewlett G; Pevzner V; Baumeister J; Weber O; Henninger K; Keldenich J; Jensen A; Kolb J; Bach U; Popp A; Mäben J; Frappa I; Haebich D; Lockhoff O; Rübsamen-Waigmann H
    Nat Med; 2002 Apr; 8(4):392-8. PubMed ID: 11927946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Helicase-primase as a target of new therapies for herpes simplex virus infections.
    James SH; Larson KB; Acosta EP; Prichard MN
    Clin Pharmacol Ther; 2015 Jan; 97(1):66-78. PubMed ID: 25670384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High conservation of herpes simplex virus UL5/UL52 helicase-primase complex in the era of new antiviral therapies.
    Collot M; Rouard C; Brunet C; Agut H; Boutolleau D; Burrel S
    Antiviral Res; 2016 Apr; 128():1-6. PubMed ID: 26826441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral bioavailability and in vivo efficacy of the helicase-primase inhibitor BILS 45 BS against acyclovir-resistant herpes simplex virus type 1.
    Duan J; Liuzzi M; Paris W; Liard F; Browne A; Dansereau N; Simoneau B; Faucher AM; Cordingley MG
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1798-804. PubMed ID: 12760851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase-primase inhibitors in their mode of interaction with the antiviral target.
    Biswas S; Kleymann G; Swift M; Tiley LS; Lyall J; Aguirre-Hernández J; Field HJ
    J Antimicrob Chemother; 2008 May; 61(5):1044-7. PubMed ID: 18299638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single amino acid substitutions in the HSV-1 helicase protein that confer resistance to the helicase-primase inhibitor BAY 57-1293 are associated with increased or decreased virus growth characteristics in tissue culture.
    Biswas S; Jennens L; Field HJ
    Arch Virol; 2007; 152(8):1489-500. PubMed ID: 17404685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High frequency of spontaneous helicase-primase inhibitor (BAY 57-1293) drug-resistant variants in certain laboratory isolates of HSV-1.
    Biswas S; Swift M; Field HJ
    Antivir Chem Chemother; 2007; 18(1):13-23. PubMed ID: 17354648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2.
    Chono K; Katsumata K; Kontani T; Kobayashi M; Sudo K; Yokota T; Konno K; Shimizu Y; Suzuki H
    J Antimicrob Chemother; 2010 Aug; 65(8):1733-41. PubMed ID: 20534624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HSV antivirals - current and future treatment options.
    Birkmann A; Zimmermann H
    Curr Opin Virol; 2016 Jun; 18():9-13. PubMed ID: 26897058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.